
    
      1. STUDY OBJECTIVES

             -  Primary Endpoints: To assess the response rate

             -  Secondary End points

                  -  To evaluate the discontinuation of corticosteroid

                  -  To assess the quality of life

        2. Treatment schedule

             -  The BSA on the date of every treatment cycle may be used as the same value of
                baseline BSA, if change of body weight is within 10% of baseline body weight.

             -  Treatment schedule consists of induction and maintenance therapy as follows

                  -  Induction - Rituximab 375 mg/m2 weekly IV for 4 consecutive weeks

                  -  Maintenance - Rituximab 375 mg/m2 monthly IV for 4 consecutive months
    
  